A Good Stock To Buy — Is Amgen

Recent moves, such as the $840 million deal for Dark Blue Therapeutics, bolster its oncology pipeline in areas like acute myeloid leukemia (AML). The Bear Case

In 2025, revenue grew 10% to $36.8 billion , with non-GAAP earnings per share (EPS) rising to $21.84 . is amgen a good stock to buy

Amgen's appeal lies in its ability to generate massive cash flow while aggressively pivoting its portfolio to offset upcoming biosimilar competition. The Bull Case Recent moves, such as the $840 million deal

Amgen (AMGN) currently presents as a for most investors, though it remains a top-tier choice for those seeking a mix of steady dividends and high-potential pipeline updates. As of late April 2026, the stock is navigating a transition from legacy blockbusters to next-generation therapies in obesity and oncology. Amgen Inc (AMGN) 30.22% since Jan 4, 2025 Closed: 23:00 • Disclaimer After hours: 03:00 Apr 27, 2026 Open342.35 Mkt cap$183.57B USD 52-wk high391.29 High348.04 P/E ratio23.91 52-wk low261.43 Div yield2.96% The Investment Thesis: Growth vs. Defense The Bull Case Amgen (AMGN) currently presents as

The market is hyper-focused on MariTide , Amgen’s monthly-dose obesity candidate, which could disrupt the current weekly-dose market dominated by Eli Lilly and Novo Nordisk.

The company recently declared a $2.52 per share quarterly dividend, offering an attractive yield of approximately 2.9-3% .